Indaptus Financial Statements From 2010 to 2025

INDP Stock  USD 2.72  0.17  6.67%   
Analyzing historical trends in various income statement and balance sheet accounts from Indaptus Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Indaptus Therapeutics' valuation are summarized below:
Market Capitalization
4.8 M
Earnings Share
(29.03)
There are currently one hundred twenty fundamental trends for Indaptus Therapeutics that can be evaluated and compared over time across competitors. Investors and active traders are advised to confirm Indaptus Therapeutics' regular fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 12/31/2025, Market Cap is likely to drop to about 241 M. In addition to that, Enterprise Value is likely to drop to about 234.8 M
Check Indaptus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Indaptus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 698, Other Operating Expenses of 14.7 M or Research Development of 9.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 53.13. Indaptus financial statements analysis is a perfect complement when working with Indaptus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Indaptus Stock
Check out the analysis of Indaptus Therapeutics Correlation against competitors.
To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.

Indaptus Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsM7.3 M22.1 M
Very volatile
Short and Long Term Debt Total80 K84.2 K986.6 K
Slightly volatile
Other Current LiabilitiesM2.4 M1.9 M
Slightly volatile
Total Current Liabilities3.4 M3.4 M3.4 M
Slightly volatile
Property Plant And Equipment Net78.1 K82.2 K3.1 M
Slightly volatile
Accounts Payable1.3 M870.2 K1.2 M
Slightly volatile
Cash5.5 M5.8 M14.4 M
Pretty Stable
Non Current Assets Total684.4 K720.4 K3.9 M
Pretty Stable
Cash And Short Term Investments5.5 M5.8 M17 M
Pretty Stable
Net Receivables23 K24.2 K637.6 K
Pretty Stable
Common Stock Shares Outstanding9.8 M9.4 M3.5 M
Slightly volatile
Liabilities And Stockholders EquityM7.3 M22.1 M
Very volatile
Other Current Assets585.3 K831.6 K599.5 K
Slightly volatile
Other Stockholder Equity77.8 M64.3 M76.4 M
Pretty Stable
Total Liabilities3.9 M3.4 M3.8 M
Pretty Stable
Total Current Assets6.3 M6.6 M18.3 M
Pretty Stable
Short Term Debt80 K84.2 K523.5 K
Slightly volatile
Common Stock114.1 K120.1 K404.5 K
Slightly volatile
Inventory41.4 K46.6 K50.8 K
Slightly volatile
Non Currrent Assets OtherM638.3 K771.8 K
Pretty Stable
Property Plant Equipment70.9 K93.5 K32.7 K
Slightly volatile
Property Plant And Equipment Gross112.6 K82.2 K39.9 K
Slightly volatile
Capital Stock87.7 K120.1 K47.8 K
Slightly volatile

Indaptus Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization698735398.9 K
Slightly volatile
Other Operating Expenses14.7 M15.4 M14.5 M
Slightly volatile
Research Development9.6 M7.3 M9.6 M
Pretty Stable
Cost Of Revenue698735398.9 K
Slightly volatile
Total Operating Expenses14.2 M15.4 M14.1 M
Slightly volatile
Interest Expense710.1 K676.3 K172.7 K
Slightly volatile
Selling General Administrative5.9 MM2.7 M
Slightly volatile
Selling And Marketing Expenses96.8 K101.8 K4.7 M
Slightly volatile
Net Interest Income710.1 K676.3 K171.7 K
Slightly volatile
Interest Income710.1 K676.3 K171.7 K
Slightly volatile
Reconciled Depreciation969735972
Slightly volatile

Indaptus Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation698735398.9 K
Slightly volatile
End Period Cash Flow5.5 M5.8 M14.4 M
Pretty Stable
Begin Period Cash Flow15.2 M13.4 M14.7 M
Slightly volatile
Net Borrowings777.2 K1.3 M579.2 K
Slightly volatile
Stock Based Compensation1.8 M2.3 M809.8 K
Slightly volatile
Change To Netincome3.4 M3.2 M949.7 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables644.5 K754.3 K462.2 K
Slightly volatile
Capex To Depreciation82.8487.2627
Pretty Stable
Inventory Turnover5.265.926.4555
Slightly volatile
Days Of Inventory On Hand44.3849.9354.4379
Slightly volatile
Payables Turnover8.0E-48.0E-42.6653
Very volatile
Average Inventory20.7 K23.3 K25.4 K
Slightly volatile
Cash Per Share0.590.618553.1239
Pretty Stable
Days Payables Outstanding453.8 K432.2 K133.1 K
Slightly volatile
Income Quality0.690.82030.8589
Pretty Stable
Current Ratio1.851.95016.2536
Pretty Stable
Capex Per Share0.01790.01884.4346
Very volatile
Average Receivables502.3 K640.1 K683.3 K
Pretty Stable
Interest Debt Per Share0.00850.0090.4023
Slightly volatile
Debt To Assets0.01090.01150.1023
Slightly volatile
Operating Cycle44.3849.9354.4379
Slightly volatile
Days Of Payables Outstanding453.8 K432.2 K133.1 K
Slightly volatile
Ebt Per Ebit0.790.97760.9796
Pretty Stable
Total Debt To Capitalization0.01980.02090.2484
Slightly volatile
Quick Ratio1.851.95016.251
Pretty Stable
Net Income Per E B T1.11.151.0164
Slightly volatile
Cash Ratio1.621.70514.4581
Very volatile
Days Of Inventory Outstanding44.3849.9354.4379
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.251.171.1344
Pretty Stable
Debt Ratio0.01090.01150.1023
Slightly volatile

Indaptus Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap241 M253.7 MB
Pretty Stable
Enterprise Value234.8 M247.1 MB
Pretty Stable

Indaptus Fundamental Market Drivers

Indaptus Upcoming Events

15th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Indaptus Therapeutics Financial Statements

Indaptus Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Indaptus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Indaptus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Indaptus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue 735.00  698.25 

Pair Trading with Indaptus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Indaptus Stock

  0.62EQ Equillium Buyout TrendPairCorr
  0.84RAC Race OncologyPairCorr
  0.73VALN Valneva SE ADR Downward RallyPairCorr

Moving against Indaptus Stock

  0.83VCYT VeracytePairCorr
  0.78DNTH Dianthus TherapeuticsPairCorr
  0.75DSGN Design TherapeuticsPairCorr
  0.64VCEL Vericel Corp OrdPairCorr
  0.56DNLI Denali TherapeuticsPairCorr
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.